European Commission authorises one of first ustekinumab biosimilars in Europe
This approval follows a development and commercialisation agreement made in September 2023 between Sandoz and Samsung Bioepis for the biosimilar ustekinumab. “approval [of Pyzchiva® (biosimilar ustekinumab)] of is a crucial step towards offering European …